Free Trial

NanoString Technologies (NSTG) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
23.06 million shs
Average Volume
34.54 million shs
Market Capitalization
$5.07 million
P/E Ratio
Dividend Yield
Price Target

NanoString Technologies MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
∞ Upside
$7.63 Price Target
Short Interest
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($3.05) to ($1.98) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

NSTG stock logo

About NanoString Technologies Stock (NASDAQ:NSTG)

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

NSTG Stock News Headlines

Retirement, saved
A new poll shows 79% of Americans are worried the country faces a retirement savings crisis. More than half say they won't have enough money to be secure once they quit work . That's why one of the most experienced men on Wall Street is coming forward today with his own personal solution.
Retirement, saved
A new poll shows 79% of Americans are worried the country faces a retirement savings crisis. More than half say they won't have enough money to be secure once they quit work . That's why one of the most experienced men on Wall Street is coming forward today with his own personal solution.
NanoString Technologies Inc (NSTG)
Why Is NanoString (NSTG) Stock Up 115% Today?
NanoString Technologies, Inc. (NSTG)
Why Is NanoString Technologies (NSTG) Stock Down 59% Today?
NanoString Technologies Files For Chapter 11 Bankruptcy Protection
NanoString feels pinch from patent lawsuits
See More Headlines
Receive NSTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoString Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Medical Instruments & Supplies
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$127.26 million
Book Value
$0.98 per share


Free Float
Market Cap
$5.07 million
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

NSTG Stock Analysis - Frequently Asked Questions

Should I buy or sell NanoString Technologies stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NSTG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NSTG, but not buy additional shares or sell existing shares.
View NSTG analyst ratings
or view top-rated stocks.

What is NanoString Technologies' stock price target for 2024?

6 brokers have issued twelve-month price targets for NanoString Technologies' shares. Their NSTG share price targets range from $2.50 to $10.00. On average, they anticipate the company's stock price to reach $7.63 in the next year.
View analysts price targets for NSTG
or view top-rated stocks among Wall Street analysts.

How were NanoString Technologies' earnings last quarter?

NanoString Technologies, Inc. (NASDAQ:NSTG) released its earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.22. The biotechnology company earned $44.16 million during the quarter, compared to analyst estimates of $42.45 million. NanoString Technologies had a negative net margin of 102.44% and a negative trailing twelve-month return on equity of 548.25%. The business's quarterly revenue was up 37.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.85) earnings per share.

What is Brad Gray's approval rating as NanoString Technologies' CEO?

36 employees have rated NanoString Technologies Chief Executive Officer Brad Gray on Brad Gray has an approval rating of 65% among the company's employees.

What other stocks do shareholders of NanoString Technologies own?
This page (NASDAQ:NSTG) was last updated on 6/22/2024 by Staff

From Our Partners